UGT1A1 Gene Polymorphism, EDTA Blood

The UGT1A1 gene polymorphism TA repeat test is a crucial tool in the realm of pharmacogenomics, offering insights into how individuals metabolize certain medications, particularly those metabolized by the UDP-glucuronosyltransferase 1A1 enzyme. This enzyme plays a pivotal role in the metabolism of various drugs, including irinotecan, a chemotherapy agent, and certain medications used to manage conditions like hyperbilirubinemia. The test specifically assesses the number of TA repeats in the UGT1A1 promoter region, with variations in repeat numbers impacting enzyme activity. For instance, individuals with a specific genotype, such as homozygous (*28/*28) or heterozygous (*1/*28), may exhibit reduced enzyme activity, potentially leading to adverse drug reactions or altered drug efficacy. By identifying these genetic variations, healthcare providers can personalize medication regimens, optimize dosages, and minimize the risk of adverse effects, thereby enhancing therapeutic outcomes and patient safety. This test exemplifies the intersection of genetics and pharmacology, highlighting the importance of tailoring medical treatments based on individual genetic profiles for precision medicine advancements. It is also used to confirm the presence of Gilbert Syndrome.